{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-016535","form_type":"8-K","ticker":"MBRX","cik":"0001659617","company_name":"Moleculin Biotech, Inc.","filed_at":"2026-05-13T12:00:58+00:00","discovered_at":"2026-05-13T12:05:00.408543+00:00","generated_at":"2026-05-13T12:08:25.148784+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"Moleculin reports preliminary blinded CR rate ~30% in MIRACLE trial; first unblinding before June 30","bullets":["Preliminary blinded CRc >40%, CR ~30% vs. historical ~17-18% for cytarabine alone.","First unblinding of 45-subject data expected before June 30, 2026; ~30 Annamycin + cytarabine vs 15 control.","56 of 90 subjects recruited in Part A as of May 1, 2026; on track for Q3 2026 completion.","Over 30% of subjects are R/R to prior venetoclax regimen, a challenging population.","Annamycin has FDA Fast Track and Orphan Drug Designations for R/R AML."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-016535","json":"https://secwatch.observer/filing/0001437749-26-016535.json","markdown":"https://secwatch.observer/filing/0001437749-26-016535.md","text":"https://secwatch.observer/filing/0001437749-26-016535.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926016535/0001437749-26-016535-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926016535/mbrx20260511_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T12:08:25.148784+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}